|
1
|
Li T, He H, Zhang E, Hu F, Wang Z, Xu J,
Zeng M and Peng B: The physiological and pathological effects of
sphingolipid metabolism and signaling in the central nervous
system. Brain Pathol. 36(e70033)2026.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alkafaas SS, Elsalahaty MI, Ismail DF,
Radwan MA, Elkafas SS, Loutfy SA, Elshazli RM, Baazaoui N, Ahmed
AE, Hafez W, et al: The emerging roles of sphingosine 1-phosphate
and SphK1 in cancer resistance: A promising therapeutic target.
Cancer Cell Int. 24(89)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hannun YA, Merrill AH and Luberto C: The
bioactive sphingolipid playbook. A primer for the uninitiated as
well as sphingolipidologists. J Lipid Res.
66(100813)2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mao C: Sphingolipid metabolism
dysregulation: A cause for lung cancer development, progression,
and resistance to therapies. Chin Med J Pulm Crit Care Med.
3:88–96. 2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sukocheva OA, Neganova ME, Aleksandrova Y,
Burcher JT, Chugunova E, Fan R, Tse E, Sethi G, Bishayee A and Liu
J: Signaling controversy and future therapeutical perspectives of
targeting sphingolipid network in cancer immune editing and
resistance to tumor necrosis factor-α immunotherapy. Cell Commun
Signal. 22(251)2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Xiong X, Zeng L, Zeng F, Huang Y and Jia
L: Bioinformatics exploration of the S1PR1 receptor in various
human cancers and its clinical relevance. Discov Oncol.
16(449)2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang Z, Zhang HM, Guo YR, Li LL and Zhang
GZ: Role of sphingosine-1-phosphate receptors in the tumor
microenvironment: Prospects for cancer immunotherapy. Eur Rev Med
Pharmacol Sci. 27:713–727. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rufail ML, Bassi R and Giussani P:
Sphingosine-1-Phosphate metabolic pathway in cancer: Implications
for therapeutic targets. Int J Mol Sci. 26(1056)2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chai Y, Xiang H, Ma Y, Feng W, Jiang Z,
Zhu Q, Chen Y, Liu Q, Zhang J, Ouyang J, et al: S1PR1 suppresses
lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1
pathway. J Exp Clin Cancer Res. 43(304)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jia W, Yuan J, Zhang J, Li S, Lin W and
Cheng B: Bioactive sphingolipids as emerging targets for signal
transduction in cancer development. Biochim Biophys Acta Rev
Cancer. 1879(189176)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Powell JA and Pitson SM: Sphingosine
1-phosphate signalling in cancer stem cells. Oncogenesis.
14(42)2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xu X, Li H, Li R, Xu Y, Xu Y, Huang H, Lv
X, Liao C, Ye J and Bo L: Mechanisms and potential therapeutic
targets of SphK1 and SphK2 in hepatocellular carcinoma. Front Med.
12(1617401)2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pyne NJ and Pyne S: Recent advances in the
role of sphingosine 1-phosphate in cancer. FEBS Lett.
594:3583–3601. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Limbu KR, Chhetri RB, Kim S, Shrestha J,
Oh YS, Baek DJ and Park EY: Targeting sphingosine 1-phosphate and
sphingosine kinases in pancreatic cancer: Mechanisms and
therapeutic potential. Cancer Cell Int. 24(353)2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hii LW, Chung FFL, Mai CW, Ng PY and Leong
CO: Sphingosine Kinase 1 signaling in breast cancer: A potential
target to tackle breast cancer stem cells. Front Mol Biosci.
8(748470)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wongviriya A, Shelton RM, Cooper PR,
Milward MR and Landini G: The relationship between
sphingosine-1-phosphate receptor 2 and epidermal growth factor in
migration and invasion of oral squamous cell carcinoma. Cancer Cell
Int. 23(65)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rostami N, Nikkhoo A, Ajjoolabady A, Azizi
G, Hojjat-Farsangi M, Ghalamfarsa G, Yousefi B, Yousefi M and
Jadidi-Niaragh F: S1PR1 as a novel promising therapeutic target in
cancer therapy. Mol Diagn Ther. 23:467–487. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lee H, Deng J, Kujawski M, Yang C, Liu Y,
Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al:
STAT3-induced S1PR1 expression is crucial for persistent STAT3
activation in tumors. Nat Med. 16:1421–1428. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nagahashi M and Miyoshi Y: Targeting
Sphingosine-1-Phosphate signaling in breast cancer. Int J Mol Sci.
25(3354)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cartier A, Leigh T, Liu CH and Hla T:
Endothelial sphingosine 1-phosphate receptors promote vascular
normalization and antitumor therapy. Proc Natl Acad Sci.
117:3157–3166. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Laroche FJF, Li S, Shen N, Hwang SK,
Nguyen G, Yu W, Wong CK, Quinton RJ, Berman JN, Liu CT, et al: S1P1
Threonine 236 phosphorylation mediates the invasiveness of
triple-Negative breast cancer and sensitivity to FTY720. Cells.
12(980)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tao YP, Zhu HY, Shi QY, Wang CX, Hua YX,
Hu HY, Zhou QY, Zhou ZL, Sun Y, Wang XM, et al: S1PR1 regulates
ovarian cancer cell senescence through the PDK1-LATS1/2-YAP
pathway. Oncogene. 42:3491–3502. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Riboni L, Abdel Hadi L, Navone SE,
Guarnaccia L, Campanella R and Marfia G: Sphingosine-1-Phosphate in
the tumor microenvironment: A signaling hub regulating cancer
hallmarks. Cells. 9(337)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang G, Zhang X, Zhou Z, Song C, Jin W,
Zhang H, Wu W, Yi Y, Cui H, Zhang P, et al: Sphingosine 1-phosphate
receptor 2 promotes the onset and progression of non-alcoholic
fatty liver disease-related hepatocellular carcinoma through the
PI3K/AKT/mTOR pathway. Discov Oncol. 14(4)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nagahashi M, Takabe K, Liu R, Peng K, Wang
X, Wang Y, Hait NC, Wang X, Allegood JC, Yamada A, et al:
Conjugated bile acid activated S1P Receptor 2 is a key regulator of
sphingosine kinase 2 and hepatic gene expression. Hepatology.
61:1216–1226. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yoshida T, Tsuchiya A, Kumagai M, Takeuchi
S, Nojiri S, Watanabe T, Ogawa M, Itoh M, Takamura M, Suganami T,
et al: Blocking sphingosine 1-phosphate receptor 2 accelerates
hepatocellular carcinoma progression in a mouse model of NASH.
Biochem Biophys Res Commun. 530:665–672. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Quinn C, Rico MC, Merali C and Merali S:
Dysregulation of S-adenosylmethionine metabolism in nonalcoholic
steatohepatitis leads to polyamine flux and oxidative stress. Int J
Mol Sci. 23(1986)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gao G, Liao W, Shu P, Ma Q, He X, Zhang B,
Qin D and Wang Y: Targeting sphingosine 1-phosphate receptor 3
inhibits T-cell exhaustion and regulates recruitment of
proinflammatory macrophages to improve antitumor efficacy of CAR-T
cells against solid tumor. J Immunother Cancer.
11(e006343)2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hirata N, Yamada S, Shoda T, Kurihara M,
Sekino Y and Kanda Y: Sphingosine-1-phosphate promotes expansion of
cancer stem cells via S1PR3 by a ligand-independent Notch
activation. Nat Commun. 5(4806)2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kim MH, Huh B, Park JW and Park WJ:
Targeting sphingolipids in breast cancer: From tumor biology to
therapeutic strategies. Oncol Res. 34(6)2026.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yuan Y, Jia G, Wu C, Wang W, Cheng L, Li
Q, Li Z, Luo K, Yang S, Yan W, et al: Structures of signaling
complexes of lipid receptors S1PR1 and S1PR5 reveal mechanisms of
activation and drug recognition. Cell Res. 31:1263–1274.
2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang Z, Pan F and Zhang G: Expression and
prognostic role of sphingosine 1-phosphate receptor 4 (S1PR4) as a
biomarker of skin cutaneous melanoma. Heliyon.
10(e27505)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Huang C, Zhu F, Zhang H, Wang N and Huang
Q: Identification of S1PR4 as an immune modulator for favorable
prognosis in HNSCC through machine learning. iScience.
26(107693)2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Long JS, Edwards J, Watson C, Tovey S,
Mair KM, Schiff R, Natarajan V, Pyne NJ and Pyne S: Sphingosine
Kinase 1 induces tolerance to human epidermal growth factor
receptor 2 and prevents formation of a migratory phenotype in
response to Sphingosine 1-Phosphate in estrogen receptor-positive
breast cancer cells. Mol Cell Biol. 30:3827–3841. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ohotski J, Long JS, Orange C, Elsberger B,
Mallon E, Doughty J, Pyne S, Pyne NJ and Edwards J: Expression of
sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is
associated with outcome in oestrogen receptor-negative breast
cancer. Br J Cancer. 106:1453–1459. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Olesch C, Sirait-Fischer E, Berkefeld M,
Fink AF, Susen RM, Ritter B, Michels BE, Steinhilber D, Greten FR,
Savai R, et al: S1PR4 ablation reduces tumor growth and improves
chemotherapy via CD8+ T cell expansion. J Clin Invest.
130:5461–5476. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang B, Wu X, Cheng J, Ye J, Zhu H and Liu
X: Regulatory role of S1P and its receptors in sepsis-induced liver
injury. Front Immunol. 16(1489015)2025.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jenne CN, Enders A, Rivera R, Watson SR,
Bankovich AJ, Pereira JP, Xu Y, Roots CM, Beilke JN, Banerjee A, et
al: T-bet-dependent S1P5 expression in NK cells promotes egress
from lymph nodes and bone marrow. J Exp Med. 206:2469–2481.
2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pei A, Lu L and Wu X: S1PR5 as a
prognostic biomarker in colon cancer: Insights into
efferocytosis-related mechanisms and immune modulation. J Mol
Histol. 56(315)2025.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Puig-Gámez M, Van Attekum M, Theis T, Dick
A and Park JE: Transcriptional signature of rapidly responding NK
cells reveals S1P5 and CXCR4 as anti-tumor response disruptors. Sci
Rep. 15(10769)2025.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Xing Z, Liu Y, Yang X, Yao Y, Chang T,
Zhou L, Luo R, Jiang L and Xue J: Multi-omics and Mendelian
randomization identify S1PR5 as a causal protective gene and NK
cell-mediated prognostic biomarker in lung adenocarcinoma. Transl
Lung Cancer Res. 14:3553–3576. 2025.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hu Y, Dong Z and Liu K: Unraveling the
complexity of STAT3 in cancer: Molecular understanding and drug
discovery. J Exp Clin Cancer Res. 43(23)2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhao J, Liu J, Lee JF, Zhang W, Kandouz M,
VanHecke GC, Chen S, Ahn YH, Lonardo F and Lee MJ: TGF-β/SMAD3
pathway stimulates Sphingosine-1 Phosphate Receptor 3 Expression
IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG
ADENOCARCINOMA PROGRESSION. J Biol Chem. 291:27343–27353.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Flori M, Schmid CA, Sumrall ET, Tzankov A,
Law CW, Robinson MD and Müller A: The hematopoietic oncoprotein
FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma
by repressing S1PR2 signaling. Blood. 127:1438–1448.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lee HM, Lo KW, Wei W, Tsao SW, Chung GTY,
Ibrahim MH, Dawson CW, Murray PG, Paterson IC and Yap LF: Oncogenic
S1P signalling in EBV-associated nasopharyngeal carcinoma activates
AKT and promotes cell migration through S1P receptor 3. J Pathol.
242:62–72. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Fong CY, Morison J and Dawson MA:
Epigenetics in the hematologic malignancies. Haematologica.
99:1772–1783. 2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Stelling A, Hashwah H, Bertram K, Manz MG,
Tzankov A and Müller A: The tumor suppressive TGF-β/SMAD1/S1PR2
signaling axis is recurrently inactivated in diffuse large B-cell
lymphoma. Blood. 131:2235–2246. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Muppidi JR, Schmitz R, Green JA, Xiao W,
Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, et al: Loss of
signaling via Gα13 in germinal center B cell-derived lymphoma.
Nature. 516:254–258. 2014.
|
|
49
|
Hait NC, Allegood J, Maceyka M, Strub GM,
Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S
and Spiegel S: Regulation of histone acetylation in the nucleus by
Sphingosine-1-Phosphate. Science. 325:1254–1257. 2009.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Xu G, Yang Z, Sun Y, Dong H and Ma J:
Interaction of microRNAs with sphingosine kinases, sphingosine-1
phosphate, and sphingosine-1 phosphate receptors in cancer. Discov
Oncol. 12(33)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cheng N and Wang GH: miR-133b, a microRNA
targeting S1PR1, suppresses nasopharyngeal carcinoma cell
proliferation. Exp Ther Med. 11:1469–1474. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhang SL and Liu L: microRNA-148a inhibits
hepatocellular carcinoma cell invasion by targeting
sphingosine-1-phosphate receptor 1. Exp Ther Med. 9:579–584.
2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Yao X, Xie L and Zeng Y: MiR-9 Promotes
angiogenesis via targeting on Sphingosine-1-Phosphate receptor 1.
Front Cell Dev Biol. 8(755)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zhang X, Liu Y, Huang WC and Zheng LC:
MiR-125b-1-3p exerts antitumor functions in lung carcinoma cells by
targeting S1PR1. Chin Med J (Engl). 131:1909–1916. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chen Y, Lin T, Tang L, He L and He Y:
MiRNA signatures in nasopharyngeal carcinoma: Molecular mechanisms
and therapeutic perspectives. Am J Cancer Res. 13:5805–5824.
2023.PubMed/NCBI
|
|
56
|
Majumdar S, Chakraborty A, Das S, Gorain
M, Chatterjee S, Dey I, Bhowmik S, Ghosh S, Banerjee S, Ahammed SM,
et al: Sponging of five tumour suppressor miRNAs by lncRNA-KCNQ1OT1
activates BMPR1A/BMPR1B-ACVR2A/ACVR2B signalling and promotes
chemoresistance in hepatocellular carcinoma. Cell Death Discov.
10(274)2024.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Baker MJ, Hampson E, Islam P, Moral RP,
Maunders EA, Hornigold K, Tsonou E, Malliri A, Hornigold DC,
Hubbard RE, et al: P-Rex1 limits the agonist-induced
internalization of GPCRs independently of its Rac-GEF activity.
Cell Rep. 44(116403)2025.PubMed/NCBI View Article : Google Scholar
|
|
58
|
D'Aprile C, Prioni S, Mauri L, Prinetti A
and Grassi S: Lipid rafts as platforms for sphingosine 1-phosphate
metabolism and signalling. Cell Signal. 80(109929)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Anwar M and Mehta D: Post-translational
modifications of S1PR1 and endothelial barrier regulation. Biochim
Biophys Acta Mol Cell Biol Lipids. 1865(158760)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Patwardhan A, Cheng N and Trejo J:
Post-Translational modifications of G Protein-Coupled receptors
control cellular signaling dynamics in space and time. Pharmacol
Rev. 73:120–151. 2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Ripoll L, von Zastrow M and Blythe EE:
Intersection of GPCR trafficking and cAMP signaling at
endomembranes. J Cell Biol. 224(e202409027)2025.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Lyapina E, Marin E, Gusach A, Orekhov P,
Gerasimov A, Luginina A, Vakhrameev D, Ergasheva M, Kovaleva M,
Khusainov G, et al: Structural basis for receptor selectivity and
inverse agonism in S1P5 receptors. Nat Commun.
13(4736)2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Kohno T, Wada A and Igarashi Y: N-Glycans
of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced
receptor internalization. FASEB J. 16:983–992. 2002.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Badawy SMM, Okada T, Kajimoto T, Ijuin T
and Nakamura S: DHHC5-mediated palmitoylation of S1P receptor
subtype 1 determines G-protein coupling. Sci Rep.
7(16552)2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Park SH, Lee YJ, Kim Y, Kim HK, Lim JH and
Jo JC: T-large granular lymphocytic leukemia. Blood Res. 58
(Suppl):S52–S57. 2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Bozzini N, Avnet S, Baldini N and Cortini
M: Epigenetic regulation mediated by sphingolipids in cancer. Int J
Mol Sci. 24(5294)2023.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Magrassi L, Marziliano N and Inzani F,
Magrassi L, Marziliano N and Inzani F: EDG3 and SHC3 on chromosome
9q22 are co-amplified in human ependymomas. Cancer Lett. 290:36–42.
2010.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Seo SH, Paul SK, Shikder M, Khanam M,
Ghosh P, Hasib TA, Ahmed KA, Sikdar S, Uddin MJ and Kwon Y: An
insight into pathophysiological features and therapeutic advances
on ependymoma. Cancers. 13(3221)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Chen H, Wang J, Zhang C, Ding P, Tian S,
Chen J, Ji G and Wu T: Sphingosine 1-phosphate receptor, a new
therapeutic direction in different diseases. Biomed Pharmacother.
153(113341)2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Pajares MJ, Alemany-Cosme E, Goñi S,
Bandres E, Palanca-Ballester C and Sandoval J: Epigenetic
regulation of microRNAs in cancer: Shortening the distance from
bench to bedside. Int J Mol Sci. 22(7350)2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Pérez-Jeldres T, Alvarez-Lobos M and
Rivera-Nieves J: Targeting Sphingosine-1-phosphate signaling in
Immune-mediated diseases: Beyond multiple sclerosis. Drugs.
81:985–1002. 2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Perry TA, Masand N, Vrzalikova K, Pugh M,
Wei W, Hollows R, Bouchalova K, Nohtani M, Fennell E, Bouchal J, et
al: The oncogenic lipid Sphingosine-1-Phosphate impedes the
phagocytosis of tumor cells by M1 macrophages in diffuse large B
cell lymphoma. Cancers. 16(574)2024.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Gong K, Dong Y, Wang L and Duan Y, Yu J,
Sun Y, Bai M and Duan Y: Nanoparticle BAF312@CaP-NP overcomes
Sphingosine-1-Phosphate Receptor-1-mediated chemoresistance through
inhibiting S1PR1/P-STAT3 axis in ovarian carcinoma. Int J
Nanomedicine. 15:5561–5571. 2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Yan Y, Bao G, Pei J, Cao Y, Zhang C, Zhao
P, Zhang Y and Damirin A: NF-κB and EGFR participate in
S1PR3-mediated human renal cell carcinomas progression. Biochim
Biophys Acta Mol Basis Dis. 1868(166401)2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu
J, Jiang Y, Li H, Zhang Q, Gao J, et al: S1P/S1PR3 axis promotes
aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
EBioMedicine. 40:210–223. 2019.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ye T, Yu J, Fang Y, Xu Z, Guo S, Zhao Z,
Li H, He H and Zhu L: Discovery and SAR study of highly selective
and potent 1,2,4-oxadiazole-based S1PR1 agonists. Eur J Med Chem.
300(118097)2025.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Bien-Möller S, Chen F, Xiao Y, Köppe H,
Jedlitschky G, Meyer U, Tolksdorf C, Grube M, Marx S, Tzvetkov MV,
et al: The putative S1PR1 modulator ACT-209905 impairs growth and
migration of glioblastoma cells in vitro. Cancers.
15(4273)2023.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Avnet S, Mizushima E, Severino B, Lipreri
MV, Scognamiglio A, Corvino A, Baldini N and Cortini M:
Antagonizing the S1P-S1P3 axis as a promising Anti-angiogenic
strategy. Metabolites. 15(178)2025.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Visentin B, Vekich JA, Sibbald BJ, Cavalli
AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, et al:
Validation of an anti-sphingosine-1-phosphate antibody as a
potential therapeutic in reducing growth, invasion, and
angiogenesis in multiple tumor lineages. Cancer Cell. 9:225–238.
2006.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Shen H, Deng Q, Chen Z, Zhang Q, Zhou X,
Chen Q and Fan J: In situ-formed immunotherapeutic hydrogel
containing sphingosine-1-phosphate for enhanced lung cancer
immunotherapy. Sci Adv. 11(eadw5001)2025.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Mishra A, Hourigan D and Lindsay AJ:
Inhibition of the endosomal recycling pathway downregulates HER2
activation and overcomes resistance to tyrosine kinase inhibitors
in HER2-positive breast cancer. Cancer Lett. 529:153–167.
2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Anu B, Namitha NN and Harikumar KB:
Chapter Nine-S1PR1 signaling in cancer: A current perspective. In:
Apoptosis in Health and Disease-Part A. vol. 125 Donev R (ed.)
Academic Press, pp259-274, 2021.
|
|
83
|
Zhang Y, Wang H, Lu J, Lv Q, Yun B, Ge Z
and Yan L: Down-regulation of S1PR2 is correlated with poor
prognosis and immune infiltrates in cervical squamous cell
carcinoma and endocervical adenocarcinoma. Int J Immunopathol
Pharmacol. 37(03946320231178131)2023.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Zhou X, Liu J, Chen X, Zhou X, Xu B, Gan G
and Chen F: S1PR3 inhibition impairs cell cycle checkpoint via the
AKT/WEE1 pathway in oral squamous cell carcinoma. J Transl Med.
23(573)2025.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Evrard M, Wynne-Jones E, Peng C, Kato Y,
Christo SN, Fonseca R, Park SL, Burn TN, Osman M, Devi S, et al:
Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral
retention of tissue-resident lymphocytes. J Exp Med.
219(e20210116)2021.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Coyle PK, Freedman MS, Cohen BA, Cree BAC
and Markowitz CE: Sphingosine 1-phosphate receptor modulators in
multiple sclerosis treatment: A practical review. Ann Clin Transl
Neurol. 11:842–855. 2024.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Shields N, Colwill M, Raspa V, Twum-Danso
Y, Poullis A, Patel K and Honap S: Sphingosine-1-Phosphate (S1P)
receptor modulators for the treatment of inflammatory bowel disease
(IBD): Mechanisms, clinical evidence, and practical insights.
Biomedicines. 13(2655)2025.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Chen S, Wu L, Lang B, Zhao G and Zhang W:
Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective
effects in central nervous system disorders. Front Pharmacol.
16(1516991)2025.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Kruschel RD, Malone K, Walsh AN, Waeber C
and McCarthy FO: Discovery of sphingosine kinase inhibition by
modified Quinoline-5,8-Diones. Pharmaceuticals (Basel).
18(268)2025.PubMed/NCBI View Article : Google Scholar
|
